Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a 75 µg sublingual tablet for sublingual use. It is indicated for the management of nocturnal polyuria (nocturia) in adults and for central diabetes insipidus, conditions characterized by impaired water balance.

GNH USA supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards and ensuring consistent quality and reliable supply chains.

Desmopressin acts on the antidiuretic hormone pathway to reduce excessive urine production.

- Nocturnal polyuria (nocturia): reduces nighttime urine volume, helping patients achieve uninterrupted sleep. - Central diabetes insipidus: replaces deficient vasopressin activity, decreasing polyuria and excessive thirst.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, often transient. - Abdominal discomfort: mild cramping or pain. - Nasal congestion: mild stuffiness. - Flushing: brief warmth or redness.

Serious or Rare Side Effects: - Hyponatremia: potentially severe electrolyte imbalance. - Seizures: secondary to profound hyponatremia. - Water intoxication: excessive fluid retention leading to cerebral edema. - Allergic reactions: rash, itching, or anaphylaxis. - Severe hypotension: rare, especially with overdose.

Before initiating therapy, clinicians should consider several safety measures.

- Assess serum sodium: monitor electrolytes prior to and during treatment. - Adjust dose in renal impairment: reduce dose or increase monitoring frequency. - Avoid concomitant antidiuretic agents: limit risk of severe hyponatremia. - Caution in elderly patients: increased sensitivity to fluid shifts. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Desmopressin may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other antidiuretic agents (e.g., carbamazepine, chlorpropamide): risk of profound hyponatremia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may potentiate antidiuretic effect.

Moderate Interactions (Monitor Closely): - Alcohol: can increase water retention and hyponatremia risk. - ACE inhibitors or ARBs: may modestly enhance antidiuretic activity. - Loop diuretics: may counteract effect, requiring dose adjustment.